Zydus Cadila receives DCGI nod for NAFLD drug Saroglitazar Mg in India
Non-Alcoholic Fatty Liver Disease (NAFLD) is a progressive disease of
the liver, which starts with fat accumulation in the liver in patients
who do not consume alcohol or take it in insignificant amounts, but
have risk factors such as overweight or obesity, diabetes mellitus
(high blood sugar), hypertension (high blood pressure) or dyslipidemia
(abnormal blood lipids).
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-cadila-receives-dcgi-nod-for-nafld-drug-saroglitazar-mg-in-india/articleshow/80022275.cms
the liver, which starts with fat accumulation in the liver in patients
who do not consume alcohol or take it in insignificant amounts, but
have risk factors such as overweight or obesity, diabetes mellitus
(high blood sugar), hypertension (high blood pressure) or dyslipidemia
(abnormal blood lipids).
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-cadila-receives-dcgi-nod-for-nafld-drug-saroglitazar-mg-in-india/articleshow/80022275.cms
Comments
Post a Comment